Treatment of pulmonary disorders associated with hypoxemia and/or smooth
muscle constriction and/or inflammation comprises administering into the lungs
as a gas compound with an NO group which does not form NO2/NOx
in the presence of oxygen or reactive oxygen species at body temperature. Treatment
of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure,
hypertension, sickle cell disease and clotting disorders, comprises administering
into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or
dissolves in blood and has an NO group which is bound in said compound so that
it does not form NO2/NOx in the presence of oxygen or reactive
oxygen species at body temperature. Exemplary of the compound administered in each
case is ethyl nitrite.